Cambridge Investment Research Advisors, Inc. Sage Therapeutics, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.9 Billion
- Q4 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 27,832 shares of SAGE stock, worth $207,070. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,832
Previous 28,548
2.51%
Holding current value
$207,070
Previous $206,000
26.7%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding SAGE
# of Institutions
194Shares Held
44.9MCall Options Held
304KPut Options Held
117K-
Black Rock Inc. New York, NY5.22MShares$38.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.84MShares$36 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.59MShares$34.2 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.46MShares$33.2 Million0.48% of portfolio
-
Rtw Investments, LP New York, NY3MShares$22.3 Million0.27% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $442M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...